Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? - Wikidata - awgldk - TriplyDB

Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

http://www.wikidata.org/entity/Q34659974

about

Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians Neoadjuvant therapy for localized pancreatic cancer: guiding principles New challenges in perioperative management of pancreatic cancer Clinical Management of Pancreatic Cancer Advances in chemotherapy for pancreatic cancer Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here?Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma Pancreatic cancer and FOLFIRINOX: a new era and new questions.Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.Update on the Management of Pancreatic Cancer in Older Adults.Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study.Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer.Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.Novel directions in neoadjuvant therapy for pancreas adenocarcinoma.Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.How the radiologist can add value in the evaluation of the pre- and post-surgical pancreas.The role of neoadjuvant therapy in pancreatic cancer: a review.Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.Histopathologic tumor invasion of superior mesenteric vein/ portal vein is a poor prognostic indicator in patients with pancreatic ductal adenocarcinoma: results from a systematic review and meta-analysis.Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?A Graded Evaluation of Outcomes Following Pancreaticoduodenectomy with Major Vascular Resection in Pancreatic Cancer.Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial.The McGill Brisbane Symptom Score in relation to survival in pancreatic adenocarcinoma: a validation study.Clinical impact of preoperative endoscopic ultrasound-guided fine-needle aspiration for pancreatic ductal adenocarcinoma.Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.The Author's Response: Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05).Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer.Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts.How to treat borderline resectable pancreatic cancer: current challenges and future directions.

P2860

Q26767041-1F751934-0DF5-4C8F-B5ED-65C22F91FBEB Q26799428-E65B4CDD-FC9D-44DE-AB4A-4B0990B1CDC2 Q28082422-5F821D94-14B5-4FB8-84EB-FA009CBDAC2E Q28084173-8585658C-D83E-47DA-B95B-3E0674ED5092 Q28085711-D65227F4-81AE-4A4C-895D-8CD837FB3DF3 Q28542043-29460EEB-C03E-477D-A41A-A9C7004CB88C Q33665450-036684B1-30AD-4744-812A-728D808B8590 Q33750803-51CCD6CA-0AC8-40BF-BC6F-0B5AD3957584 Q33751263-C88E42E0-1F0E-4FF9-842E-6F7E11E93942 Q33982773-AA2F14F6-C38D-4DD1-AC3A-CA09578F424F Q35147520-2D0C70B3-7BB5-42BA-885F-AC34680BA109 Q35528619-D8808BEA-C023-410E-8730-512391854C79 Q35755386-F10ECE01-503F-49A8-8475-5947A4DC3BF5 Q35778600-36CE5C8A-E888-4D5F-A6C6-72FDA51A7589 Q36095529-965C61F6-E483-4EE3-AD7B-3DA1EF339568 Q36152545-E90E1C70-7642-42D1-A18B-062ECE094C30 Q36159880-669228E5-EC80-4423-815A-60A08CC08CE6 Q36558415-AF90C171-7E46-4AF4-86E8-C5D974B6A0EE Q36757638-C8537550-5528-4FA2-9219-5CE4CF3397A0 Q37555302-BF7658F0-7E57-4824-8F9C-46C9FC5ED98A Q38357201-BA82A021-6ED6-4CE9-B1F2-85BE10BBBF25 Q38566193-F0429E52-B55D-4407-A017-0195ABEEE520 Q38611312-C7F46BF9-E9E9-446B-8642-E2B72729E8DB Q38734981-13D82540-BE79-4E08-ACC4-C65B573678EA Q38753432-F224D166-3F27-4461-BA3D-B6B14D5859A2 Q38828303-78B6A44A-EBD9-4F7E-94E2-352B64D3EA23 Q38905077-629ACBE1-D711-425F-A142-4BD8D8099AB2 Q38950663-FD82FF76-33D5-412F-A03D-55C6DAE6EC0E Q39371358-B8C3A08C-9D1B-4CDC-AFEB-C11CE7F5ED9A Q39390859-46CCE236-E619-492B-9DE9-11EBC4973DFF Q40527810-3393E841-034E-470B-BDEC-1CD2EA862D88 Q40630889-9967973F-26FB-44B6-9B15-2D70C727CEAB Q40734249-9902F8AD-4928-42CF-9880-555705E87D56 Q40805384-D4D2D92B-47B1-4A1F-A3C6-387D0F909EA0 Q42374126-D2A313D9-C180-4F30-A636-7719E9FD5649 Q42380400-289DEB00-D2A8-4637-B78A-6F5ABEAD5971 Q42698514-B55FA911-6361-4278-8DE1-248C04C9761A Q47103986-2C3E702D-262C-4285-9377-886BC3C91C4E Q47317142-F5E3AF28-8CFF-4C0A-B0AA-FC73B8F92194 Q47728528-54391190-CDA9-4F83-AF99-EC2C5A651204

P2860

Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

http://www.wikidata.org/entity/Q34659974

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Neoadjuvant FOLFIRINOX for bor ...... cer: a new treatment paradigm?

@ast

Neoadjuvant FOLFIRINOX for bor ...... cer: a new treatment paradigm?

@en

Neoadjuvant FOLFIRINOX for bor ...... cer: a new treatment paradigm?

@nl

type

label

Neoadjuvant FOLFIRINOX for bor ...... cer: a new treatment paradigm?

@ast

Neoadjuvant FOLFIRINOX for bor ...... cer: a new treatment paradigm?

@en

Neoadjuvant FOLFIRINOX for bor ...... cer: a new treatment paradigm?

@nl

prefLabel

Neoadjuvant FOLFIRINOX for bor ...... cer: a new treatment paradigm?

@ast

Neoadjuvant FOLFIRINOX for bor ...... cer: a new treatment paradigm?

@en

Neoadjuvant FOLFIRINOX for bor ...... cer: a new treatment paradigm?

@nl

P1433

Q34659974-04CE041D-545C-417E-808D-842F0E39459B

P1476

Q34659974-B6F989B0-C056-4D07-8D7B-BB5FFD00D1CC

P2093

Q34659974-01B421D4-7FCB-42CC-AD82-0A82E6C20CFF

Q34659974-03BC506E-5EA5-4A1A-AA21-E958F280BF13

Q34659974-39AA9A14-A27F-4DA1-88B9-E22EBD13312E

Q34659974-426DC3C6-754A-48D6-B323-C2CA3478563B

Q34659974-6C8A34E3-89D1-46FC-8E0C-0D7D5122A7A2

Q34659974-6E1C5DBA-20AD-4F05-B742-2620A02309CA

Q34659974-8330F47E-5DF4-44BD-A221-1CBB67735512

Q34659974-AC8D1F5E-9831-49C6-B4D4-858DC9B7715E

Q34659974-C3450FF6-84CC-4E5C-BA5C-6D1755C30858

Q34659974-C7B9F675-BC0B-4125-8738-0D869BEA12BE

P2860

Q34659974-035615BA-3CBF-4A22-AB59-8CB09A8D9F9D

Q34659974-3242EF15-3C7F-44AF-A487-07CBA54B4640

Q34659974-418C8E01-8232-4AF6-A836-9D8E1C52B3DD

Q34659974-4C0AE379-1493-44D6-944E-8358DF23573C

Q34659974-CE56AF50-965F-445D-9757-CF4726854806

Q34659974-D2976E08-C63F-425A-A95E-3DA68E2DFDD9

Q34659974-EA0FECC1-6C25-4BF3-8474-CC3E31DE01CB

P304

Q34659974-CEDDF080-C852-40A3-B172-7C67E57CBA41

P31

Q34659974-A7C16789-DBDC-48CF-8810-0DC2E20CF041

P356

Q34659974-0E32A1CB-C959-490B-A9AD-D4DB3B563B2D

P433

Q34659974-12A71990-FD36-4693-A1BC-6495D89DB26B

P478

Q34659974-3F153406-4B08-4F42-8B79-820FC2E2DFFF

P577

Q34659974-D38F67A6-9483-477D-B0CB-54F41435093E

P5875

Q34659974-404A2ED7-5DCB-4ECB-B26D-1D9B1A9C2F7C

P698

Q34659974-3D50A0F1-5359-4987-A1E1-591191A9A311

P921

Q34659974-8C5F8C43-1C86-431F-9425-2B3DF5904642

P932

Q34659974-945232AF-BD55-4052-ADAB-E4E3BAC2B5AD

P356

THEONCOLOGIST.2013-0273

P1433

P1476

Neoadjuvant FOLFIRINOX for bor ...... cer: a new treatment paradigm?

@en

P2093

Anna Mahmoud

http://www.w3.org/2001/XMLSchema#string

Ben George

http://www.w3.org/2001/XMLSchema#string

Beth Erickson

http://www.w3.org/2001/XMLSchema#string

Douglas B Evans

http://www.w3.org/2001/XMLSchema#string

Huamin Wang

http://www.w3.org/2001/XMLSchema#string

James P Thomas

http://www.w3.org/2001/XMLSchema#string

Kathleen K Christians

http://www.w3.org/2001/XMLSchema#string

Lauren Wiebe

http://www.w3.org/2001/XMLSchema#string

Paul Ritch

http://www.w3.org/2001/XMLSchema#string

Susan Tsai

http://www.w3.org/2001/XMLSchema#string

P2860

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.

Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

The added value of multidisciplinary care for patients with pancreatic cancer.

Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

P304

266-274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2013-0273

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260381907

http://www.w3.org/2001/XMLSchema#string

P698

24569947

http://www.w3.org/2001/XMLSchema#string

P921

Aizkuņģa dziedzeris

P932

3958454

http://www.w3.org/2001/XMLSchema#string